LH-RH agonists are not useful in treatment for LAM

R. Cassandro, L. Longo, A. Caminati, M. Mirenda, G. Paciocco, S. Harari (Milan, Italy)

Source: Annual Congress 2005 - Advancements in diffuse parenchymal lung disease
Session: Advancements in diffuse parenchymal lung disease
Session type: Poster Discussion
Number: 1796
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Cassandro, L. Longo, A. Caminati, M. Mirenda, G. Paciocco, S. Harari (Milan, Italy). LH-RH agonists are not useful in treatment for LAM. Eur Respir J 2005; 26: Suppl. 49, 1796

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids
Source: Eur Respir J 2006; 27: 511-516
Year: 2006



Multiple organ leiomyomatosis in patients with pulmonary lymphangioleiomyomatosis and experience of treatment with Zoladex, a depot of gonadotropin-releasing hormone agonist
Source: Eur Respir J 2003; 22: Suppl. 45, 48s
Year: 2003

A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016



Growth hormone (GH) response to GH-releasing hormone (GHRH) in asthmatic patients during long-term inhaled corticosteroids (ICS) treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 419s
Year: 2003

Growth hormone-releasing hormone receptor antagonist MIA-602 modulates mouse lung inflammation and fibrosis due to bleomycin
Source: International Congress 2018 – New insights in the signalling pathways that underlie IPF pathophysiology
Year: 2018



Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

The efficacy and safety of long-acting muscarinic antagonist treatment for COPD
Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma
Year: 2019


The efficacy of steroid with pentoxifylline in steroid resistant sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 542s
Year: 2006

In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist
Source: Eur Respir J 2007; 30: Suppl. 51, 25s
Year: 2007

AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011


Association of adrenal response in asthmatic children on inhaled steroids with polymorphisms in the genes of glucocorticoid receptor (GR) and corticotropin releasing hormone receptor 1 (CRHR1)
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009


Effect of long-acting β2 adrenergic receptor agonists and glucocorticoids on extracellular matrix production
Source: Eur Respir J 2001; 18: Suppl. 33, 475s
Year: 2001

Glycosaminoglycan synthesis is modulated by glucocorticoids and beta2-adrenergic agonists
Source: Eur Respir J 2004; 24: Suppl. 48, 95s
Year: 2004

Biomarker-high patients and steroid responsiveness
Source: International Congress 2018 – PG17 Asthma phenotyping
Year: 2018


Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Low-dose inhaled glucocorticoids are more effective tham LTRA in improving functional data in asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004

Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001


In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407
Source: Eur Respir J 2007; 30: Suppl. 51, 26s
Year: 2007

Impairment of β2-adrenoceptor agonist relaxation by cytokines is prevented by concomitant glucocorticoid treatment for formoterol but not for salmeterol in mouse trachea
Source: Eur Respir J 2007; 30: Suppl. 51, 714s
Year: 2007